Candel Therapeutics, Inc. Common Stock vs. Krystal Biotech, Inc. Common Stock
CADL
Candel Therapeutics, Inc. Common Stock
$13.13 +6.32%
VS KRYSKrystal Biotech, Inc. Common Stock
$346.58 +2.84%
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 5 of 6 compared factors.
Size & Scale
| CADL | KRYS | |
|---|---|---|
| Market Cap | $1.00 billion | $10.26 billion |
| Revenue (TTM) | — | $440.48 million |
| Net Income (TTM) | $-88,531,000 | $241.47 million |
KRYS leads on 3 of 3 size & scale factors.
Valuation
| CADL | KRYS | |
|---|---|---|
| P/E Ratio | — | 43.43 |
| Price / Book | 7.97 | 7.55 |
| Price / Sales | — | 23.29 |
KRYS leads on 1 of 1 valuation factors.
Profitability
| CADL | KRYS | |
|---|---|---|
| Net Margin | — | 54.82% |
| Return on Equity | -70.19% | 17.77% |
KRYS leads on 1 of 1 profitability factors.
Risk & Sentiment
| CADL | KRYS | |
|---|---|---|
| Short Interest | 0.04% | 0.11% |
CADL leads on 1 of 1 risk & sentiment factors.
Dig deeper: CADL overview, CADL financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.